Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma-Reference-Cited by-同舟云学术

Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma

Published:1996-01 Issue:1 Volume:92 Page:44-48
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:British Journal of Haematology

Author:

Lokhorst Henk,Sonneveld Pieter,Wijermans Pierre,Van Marwijk Kooy Marinus,Th. Meuwissen Otger,Van Oers Rien,Van Der Griend René,Dekker Adriaan

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.1996.00306.x/fullpdf

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hematopoietic Stem Cell Collection in Multiple Myeloma Patients: Influence of the Lenalidomide-Based Therapy and Mobilization Regimen Prior to Auto-HSCT;Clinical oncohematology;2018

2. The role of tandem stem cell transplantation for multiple myeloma patients;Expert Opinion on Biological Therapy;2016-02-06

3. Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables;Journal of Clinical Apheresis;2013-12-18

4. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation;European Journal of Haematology;2011-07-15

5. The use of intravenous intermediate dose melphalan and dexamethasone as induction treatment in the management of de novo multiple myeloma;European Journal of Haematology;2009-04-24